Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Esophageal Squamous Cell Carcinoma AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43858   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    69 result(s) found for: Esophageal Squamous Cell Carcinoma AND Cancer. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-003415-26 Sponsor Protocol Number: 2021-003415-26 Start Date*: 2022-01-07
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients
    Medical condition: HER2 positive Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041824 Squamous cell carcinoma of esophagus LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041825 Squamous cell carcinoma of esophagus NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056104 Squamous cell carcinoma of oesophagus LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001016-21 Sponsor Protocol Number: AGMT_ECa Start Date*: 2008-08-28
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinom
    Medical condition: Unbehandeltes, histologisch gesichertes, nicht-metastasiertes Ösophaguskarzinom (Plattenepithelkarzinom)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056104 Squamous cell carcinoma of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019595-79 Sponsor Protocol Number: UMCNONCO200905 Start Date*: 2010-10-15
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: A randomised phase II study of radio-chemotherapy with or without panitumumab (Vectibix®) in irresectable squamous cell carcinoma or adenocarcinoma of the oesophagus (Panoramic)
    Medical condition: histology proven irresectable squamous cell or adenocarcinoma of the oesophagus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055476 Esophageal squamous cell carcinoma LLT
    12.1 10055458 Esophageal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000533-40 Sponsor Protocol Number: CIBI308A301 Start Date*: 2020-10-05
    Sponsor Name:Innovent Biologics (Suzhou) Co., Ltd.
    Full Title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectab...
    Medical condition: Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030187 Oesophageal squamous cell carcinoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058527 Oesophageal squamous cell carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001178-31 Sponsor Protocol Number: YO42137 Start Date*: 2020-08-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WH...
    Medical condition: Esophageal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) PT (Ongoing) HU (Completed) FR (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000587-28 Sponsor Protocol Number: BGB-A317-306 Start Date*: 2019-06-06
    Sponsor Name:BeiGene, Ltd., c/o BeiGene USA, Inc.
    Full Title: A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with...
    Medical condition: Unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) BE (Ongoing) ES (Ongoing) PL (Ongoing) CZ (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003699-30 Sponsor Protocol Number: BGB-A317-302 Start Date*: 2018-06-08
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody Tislelizumab (BGB-A317) versus Chemotherapy as Second Line Treatment in Patients with Adv...
    Medical condition: Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021439-16 Sponsor Protocol Number: E-DIS-1006 Start Date*: 2010-10-22
    Sponsor Name:Centre Oscar Lambret
    Full Title: Etude de phase II randomisée chez des patients porteurs d’un cancer épidermoïde métastatique de l’œsophage évaluant l’intérêt de la poursuite ou non d’un traitement cytotoxique chez des patients no...
    Medical condition: Cancer épidermoïde métastatique de l'oesophage
    Disease: Version SOC Term Classification Code Term Level
    12.1 10041824 Squamous cell carcinoma of esophagus LLT
    12.1 10051671 Metastases to oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001001-22 Sponsor Protocol Number: D910SC00001 Start Date*: 2021-03-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advance...
    Medical condition: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015366 Esophageal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Trial now transitioned) PL (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000935-42 Sponsor Protocol Number: IJB-GASTON-002-ARTEMIS-Eso Start Date*: 2017-04-20
    Sponsor Name:Institut Jules Bordet
    Full Title: Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction can...
    Medical condition: Adenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005391-13 Sponsor Protocol Number: OCTO_005 Start Date*: 2008-10-20
    Sponsor Name:University of Oxford [...]
    1. University of Oxford
    2. Royal Wolverhampton Hospitals NHS Trust
    Full Title: Cancer Oesophagus Gefitinib(COG) - Phase III randomised, double-blind, placebo-controlled trial of gefitinib (Iressa®) versus placebo in oesophageal cancer progressing after chemotherapy.
    Medical condition: Oesophageal cancer (adenocarcinoma and squamous cancers).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001141 Adenocarcinoma LLT
    9.1 10041824 Squamous cell carcinoma of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001514-20 Sponsor Protocol Number: CA209-648 Start Date*: 2017-06-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent o...
    Medical condition: Inoperable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Ongoing) FR (Ongoing) DK (Ongoing) PT (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005556-10 Sponsor Protocol Number: CA209-577 Start Date*: 2016-05-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
    Medical condition: Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030191 Oesophageal squamous cell carcinoma stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030190 Oesophageal squamous cell carcinoma stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030143 Oesophageal adenocarcinoma stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030144 Oesophageal adenocarcinoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) DE (Trial now transitioned) BE (Ongoing) DK (Trial now transitioned) NL (Ongoing) FR (Trial now transitioned) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016584-10 Sponsor Protocol Number: SAKK75/08 Start Date*: 2010-08-02
    Sponsor Name:Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK
    Full Title: Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial
    Medical condition: Locally advanced esophageal carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041824 Squamous cell carcinoma of esophagus LLT
    20.0 100000004864 10056092 Adenocarcinoma of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002617-35 Sponsor Protocol Number: BUL-5/ESD Start Date*: 2019-08-20
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for p...
    Medical condition: Prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030186 Oesophageal squamous cell carcinoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.0 10017947 - Gastrointestinal disorders 10004137 Barrett's oesophagus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) PT (Trial now transitioned) NL (Trial now transitioned) BE (Completed) SE (Trial now transitioned) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000640-10 Sponsor Protocol Number: 2012/VCC/0009 Start Date*: 2012-12-13
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carbopla...
    Medical condition: Histologically confirmed operable oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10056104 Squamous cell carcinoma of oesophagus LLT
    14.1 100000004864 10056092 Adenocarcinoma of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002181-41 Sponsor Protocol Number: ACT16902 Start Date*: 2021-12-08
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa...
    Medical condition: Advanced and metastatic gastrointestinal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Temporarily Halted) IT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004658-32 Sponsor Protocol Number: BGB-A317-A1217-203 Start Date*: 2021-06-03
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A...
    Medical condition: PD-L1 vCPS ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005443-76 Sponsor Protocol Number: MK-3475-06B Start Date*: 2022-07-14
    Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatm...
    Medical condition: Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10030186 Oesophageal squamous cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005405-26 Sponsor Protocol Number: MK-3475-06A Start Date*: 2022-07-25
    Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER...
    Medical condition: Esophageal Squamous Cell Carcinoma (ESCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10030186 Oesophageal squamous cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 11:38:10 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA